(Q40025452)

16 September 2017

title

Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines (English)

1 reference

16 September 2017

1 reference

H Sasaki

1

1 reference

16 September 2017

J Hayakawa

2

1 reference

16 September 2017

Y Terai

3

1 reference

16 September 2017

M Kanemura

4

1 reference

16 September 2017

A Tanabe-Kimura

5

1 reference

16 September 2017

H Kamegai

6

1 reference

16 September 2017

H Seino-Noda

7

1 reference

16 September 2017

S Ezoe

8

1 reference

16 September 2017

I Matsumura

9

1 reference

16 September 2017

Y Kanakura

10

1 reference

16 September 2017

M Sakata

11

1 reference

16 September 2017

K Tasaka

12

1 reference

16 September 2017

M Ohmichi

13

1 reference

16 September 2017

language of work or name

English

0 references

publication date

14 January 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

27

1 reference

16 September 2017

issue

19

1 reference

16 September 2017

page(s)

2737-2745

1 reference

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Involvement of estrogen receptor beta in ovarian carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogens and epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Signal transduction. A new mediator for an old hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen Inhibits Paclitaxel-Induced Apoptosis via the Phosphorylation of Apoptosis Signal-Regulating Kinase 1 in Human Ovarian Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen induction of insulin-like growth factors and myc proto-oncogene expression in the uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Cloning of the human oestrogen receptor cDNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Menopausal hormone replacement therapy and risk of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Endocrine Factors in Common Epithelial Ovarian Cancer*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Oestrogen-replacement therapy and risk of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210926

1 reference

Dimensions Publication ID

16 September 2017

1033081633

0 references

1 reference